Severe Asthma in School-Age Children: An Updated Appraisal on Biological Options and Challenges in This Age Group
Children,
Journal Year:
2025,
Volume and Issue:
12(2), P. 167 - 167
Published: Jan. 29, 2025
This
review
examines
the
growing
role
of
biological
therapies
in
managing
severe
asthma
children
aged
6–11
years.
Severe
asthma,
characterized
by
persistent
symptoms
and
frequent
exacerbations,
presents
significant
challenges
pediatric
care.
Biologic
treatments,
including
mepolizumab,
omalizumab,
dupilumab,
provide
targeted
interventions
for
patients
with
high
eosinophilic
inflammation
or
allergic
(T2-high
asthma).
Alongside
their
therapeutic
benefits,
evaluates
safety
profiles
these
biologics,
highlighting
potential
side
effects
necessity
monitoring
during
long-term
use.
Cost
considerations
treatment
adherence
also
emerge
as
important
that
need
to
be
addressed
clinical
practice.
Additionally,
emphasizes
identifying
who
would
derive
most
benefit
from
biologic
therapies,
advocating
development
biomarkers
aid
decisions.
Emerging
such
tezepelumab,
are
introduced
promising
alternatives
target
upstream
inflammatory
pathways,
offering
hope
treating
T2-low
forms,
which
currently
lack
effective
options
children.
Language: Английский
Management of severe asthma in children: current insights and future directions
Expert Review of Clinical Immunology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 13, 2025
Severe
pediatric
asthma
represents
a
critical
challenge
in
respiratory
medicine,
affecting
small
but
significant
subset
of
children
with
disproportionate
morbidity
and
healthcare
burden.
Its
complexity
arises
from
diverse
phenotypes,
endotypes,
inflammatory
pathways
that
complicate
diagnosis
management.
Recent
advances
precision
particularly
biologic
therapies
targeting
Type
2
inflammation,
offer
new
opportunities
for
improved
outcomes.
This
review
synthesizes
current
knowledge
on
severe
asthma,
emphasizing
the
pathophysiology,
clinical
therapeutic
advancements.
It
explores
role
biomarkers
endotypes
guiding
personalized
therapy
critically
examines
challenges
such
as
non-Type
barriers
to
access,
variability
treatment
response.
A
comprehensive
literature
search
was
conducted,
focusing
therapies,
diagnostic
innovations,
emerging
care
models.
Despite
progress,
remain
achieving
standardized
response
definitions,
validating
biomarkers,
addressing
cost
barriers.
Early
initiation
high-risk
multidisciplinary
are
advancing
Future
efforts
should
prioritize
predictive
algorithms,
innovative
equitable
access
shift
symptom
control
disease
prevention,
potentially
redefining
paradigm.
Language: Английский